Has Georges Azzi, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,171,998 in general payments to Georges Azzi, MD across 1,341 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Georges Azzi, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Georges Azzi, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Georges Azzi, MD

Hematology & Oncology · Fort Lauderdale, FLNPI 1265743017

Payments from drug & device makers

$2,171,998in general payments, 2019–2025

Across 1,341 payments — averaging $1619.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boehringer Ingelheim Pharma GmbH & Co.kg$901K
Boehringer Ingelheim$354K
AstraZeneca$322K
Janssen Research & Development, LLC$187K
Pfizer$139K
E.r. Squibb & Sons, L.L.C.$69K
plus $199K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boehringer Ingelheim Pharma GmbH & Co.kg	8	$900,963
Boehringer Ingelheim	13	$353,609
AstraZeneca(2 entities)	82	$322,256
Janssen Research & Development, LLC	37	$187,026
Pfizer	158	$139,101
E.r. Squibb & Sons, L.L.C.	46	$69,414
Adaptive Biotechnologies Corporation	48	$65,593
Seagen Inc.	35	$46,004
Astellas Pharma Global Development	11	$29,877
Astellas Pharma US Inc	43	$16,420
Gilead(2 entities)	18	$6,397
Novartis	131	$4,683
Mirati Therapeutics, Inc.	11	$4,083
Exelixis Inc.	17	$3,827
Daiichi Sankyo Inc.	99	$3,483
Taiho Oncology, Inc.	6	$2,615
Avyxa Pharma, LLC	5	$2,581
Boehringer Ingelheim Espana S.A.	20	$2,000
Johnson & Johnson(2 entities)	102	$1,677
Tempus AI, Inc	18	$1,332
Merck	54	$1,029
Genentech USA, Inc.	42	$873
Lilly USA, LLC	32	$563
Bristol Myers Squibb	28	$526
Puma Biotechnology, Inc.	15	$466
GSK	22	$459
AbbVie	21	$442
Array Biopharma Inc	24	$431
Takeda Pharmaceuticals U.S.A., Inc.	20	$387
Incyte Corporation	10	$378
Eisai Inc.	15	$335
Deciphera Pharmaceuticals Inc.	11	$262
Amgen	16	$245
Bayer	11	$231
Tersera Therapeutics LLC	9	$226
Ipsen Biopharmaceuticals, Inc	7	$221
Pharmaessentia USA Corporation	7	$157
Karyopharm Therapeutics Inc.	5	$105
Rigel Pharmaceuticals, Inc.	4	$100
Blue Earth Diagnostics	5	$95
EMD Serono, Inc.	5	$93
Recordati_rare_diseases_inc.	4	$93
Stemline Therapeutics Inc.	3	$91
ADC Therapeutics America, Inc.	4	$84
Apellis Pharmaceuticals, Inc.	3	$82
Dova Pharmaceuticals	5	$78
Jazz Pharmaceuticals Inc.	4	$71
Sobi, Inc	3	$67
Alnylam Pharmaceuticals Inc.	3	$64
Blueprint Medicines Corporation	2	$59
Legend Biotech USA Inc.	2	$59
Sanofi	3	$51
Kyowa Kirin, Inc.	2	$46
Foundation Medicine, Inc.	2	$43
Immunogen, Inc.	2	$41
Janssen Scientific Affairs, LLC	4	$39
Sun Pharmaceutical Industries Inc.	2	$35
Advanced Accelerator Applications	2	$30
Fresenius Kabi USA, LLC	1	$30
Intuitive Surgical	1	$30

How this compares

$2,171,998 in reported general payments places this provider in the 90th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida →

Medicare billing

Part B allowed, 2024

$148,163

Medicare patients

376

Services billed

1,287

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Fort Lauderdale

Edgardo SantosFort Lauderdale$2.3M
Carl LandgrenMiami$47.8M
Julio ChavezTampa$16.4M
Steven AttiaJacksonville$13.9M
Santosh NairOrange City$13.5M
Frederick LockeTampa$12.8M
Tarek MekhailOrlando$11.2M
Carlos AlemanyOrlando$10.9M
Thomas GeorgeGainesville$10.3M
Sikander AilawadhiJacksonville$9.8M

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →